Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects
Autore:
Ruwe, FJL; Smulders, RA; Kleijn, HJ; Hartmans, HLA; Sitsen, JMA;
Indirizzi:
NV Organon, Clin Dev Dept, NL-5340 BH Oss, Netherlands NV Organon Oss Netherlands NL-5340 BH Dept, NL-5340 BH Oss, Netherlands NV Organon, Dept Drug Metab & Kinet, NL-5340 BH Oss, Netherlands NV Organon Oss Netherlands NL-5340 BH Kinet, NL-5340 BH Oss, Netherlands Kendle Clin Pharmacol Unit, NL-3584 CJ Utrecht, Netherlands Kendle Clin Pharmacol Unit Utrecht Netherlands NL-3584 CJ t, Netherlands
Titolo Testata:
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
fascicolo: 6, volume: 16, anno: 2001,
pagine: 449 - 459
SICI:
0885-6222(200108)16:6<449:MAPADI>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; WITHDRAWAL SYNDROME; PHARMACOKINETICS; PERFORMANCE; MANAGEMENT; DISORDER; HUMANS; SLEEP;
Keywords:
mirtazapine; paroxetine; cytochrome P-450; drug-drug interaction; pharmacokinetics;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Sitsen, JMA NV Organon, Clin Dev Dept, POB 20, NL-5340 BH Oss, NetherlandsNV Organon POB 20 Oss Netherlands NL-5340 BH Oss, Netherlands
Citazione:
F.J.L. Ruwe et al., "Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects", HUM PSYCHOP, 16(6), 2001, pp. 449-459

Abstract

Paroxetine inhibits cytochrome P-450 2D6, which is involved in the metabolism of mirtazapine. The possible drug-drug interaction between two pharmacologically distinct antidepressants, mirtazapine and paroxetine, has been investigated in a randomized, three-way crossover study in 24 healthy male and female subjects. After a titration phase of 3 days, each subject receivedsingle daily doses of 30 mg mirtazapine, 40 mg paroxetine or the combination for 6 days. Assessments included serial blood sampling for pharmacokinetics at steady state cognitive testing using the test battery of CDR Ltd, a visual analogue mood rating scale (Bond and Lader) and the Leeds Sleep Evaluation Questionnaire. Paroxetine inhibits the metabolism of mirtazapine, asshown by increases of approximately 17% and 25% of the 24 h AUC's of mirtazapine and its demethyl metabolite, respectively. Mirtazapine did not alterthe pharmacokinetics of paroxetine. The combined administration of mirtazapine and paroxetine probably does not alter cognitive functioning or resultin major changes on the visual analogue mood rating scale and Sleep Evaluation Questionnaire, compared with the administration of either drug alone. The incidence of adverse events was lower during combined administration ofmirtazapine and paroxetine than during administration of either drug alone. Fatigue, dizziness, headache, nausea, anxiety and somnolence were the most common adverse events during combined administration. These data suggest that the combination of mirtazapine and paroxetine is unlikely to lead to clinically relevant drug-drug interactions and can be used without dose adjustment of either drug. The combination may even be better tolerated than either drug alone. Copyright (C) 2001 John Wiley & Sons, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/02/20 alle ore 04:07:40